P1.15-11 Durvalumab + Olaparib vs Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: Outcomes from the Phase 2 ORION Study

Abstract

Immunotherapy alone or combined with chemotherapy (CT) has transformed first-line treatment of metastatic NSCLC. Nevertheless, median PFS typically remains <1 year in clinical studies, highlighting the need for novel treatment strategies. Increased DNA damage triggered through poly (ADP-ribose) polymerase (PARP) inhibition may modify tumour immunogenicity, sensitising tumours to immunotherapy. ORION evaluates the efficacy and safety of durvalumab (D; PD-L1 inhibitor) plus olaparib (O; PARP inhibitor) as maintenance therapy.